Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?The Motley Fool • 05/27/26
Ozempic, Other Weight Drug Users Cut Back On Eating Out. What That Means For Restaurants.Investors Business Daily • 05/26/26
4 Large-Cap Pharma Stocks to Buy as Industry Recovery AcceleratesZacks Investment Research • 05/26/26
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and strokeGlobeNewsWire • 05/26/26
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to KnowZacks Investment Research • 05/25/26
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)GlobeNewsWire • 05/22/26
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its classGlobeNewsWire • 05/22/26
Focus: Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors sayReuters • 05/21/26
Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche BankProactive Investors • 05/20/26
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss PartyThe Motley Fool • 05/19/26
Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi saysProactive Investors • 05/18/26
As millions flock to GLP-1s, doctors warn of a rise in frailty caused by rapid muscle wastingWSJ • 05/17/26